Lumos Pharma, Inc. (LUMO)
Stock Price:
$15.15 USD
0.81 (5.65%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
125.64M |
| Revenue (ttm) |
851,000 |
| Net Income (ttm) |
-32.61M |
| Shares Out |
8.29M |
| EPS (ttm) |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 7, 2020 |
| Last Price |
$15.15 |
| Previous Close |
$14.34 |
| Change ($) |
0.81 |
| Change (%) |
5.65% |
| Day's Open |
14.25 |
| Day's Range |
14.24 - 15.16 |
| Day's Volume |
32,126 |
| 52-Week Range |
6.74 - 32.40 |
More Stats
| Market Cap |
125.64M |
| Enterprise Value |
40.91M |
| Earnings Date (est) |
Aug 13, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
8.29M |
| Float |
n/a |
| EPS (basic) |
n/a |
| EPS (diluted) |
n/a |
| FCF / Share |
-11.84 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
224,845 |
| Short Ratio |
6.80 |
| Short % of Float |
3.91% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
147.63 |
| PB Ratio |
0.96 |
| Revenue |
851,000 |
| Operating Income |
-39.69M |
| Net Income |
-32.61M |
| Free Cash Flow |
-25.93M |
| Net Cash |
84.73M |
| Net Cash / Share |
10.22 |
| Gross Margin |
n/a |
| Operating Margin |
-4,663.34% |
| Profit Margin |
-3,908.80% |
| FCF Margin |
-3,047.24% |
| ROA |
n/a |
| ROE |
n/a |
| ROIC |
-244.00% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (2)
| Buy |
2 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$25.50*
(68.32% upside)
Low
18.0
Current: $15.15
High
33.0
Target: 25.50
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 0.94 | 12.47 | 28.71 | 35.77 | 68.50 | 173 | 1.09 | 1.69 | 1.87 | 2.08 |
| Revenue Growth | -92.5% | -56.55% | -19.73% | -47.78% | -60.31% | 15690.67% | -35.21% | -9.88% | -9.96% | - |
| Gross Profit | 0.94 | 12.47 | 28.71 | 35.77 | 68.50 | 173 | 1.09 | 1.69 | 1.87 | 2.08 |
| Operating Income | -45.13 | -62.44 | -72.88 | -90.76 | -33.60 | 118 | -31.14 | -23.26 | -18.06 | -16.66 |
| Net Income | -42.99 | -53.60 | -71.95 | -85.16 | -40.38 | 96.02 | -31.18 | -23.32 | -18.09 | -16.21 |
| Shares Outstanding | 4.14 | 4.13 | 3.48 | 3.22 | 3.18 | 3.09 | 2.81 | 2.31 | 0.67 | 0.37 |
| Earnings Per Share | -10.35 | -12.96 | -20.70 | -26.46 | -12.69 | 27.81 | -11.07 | -10.08 | -26.82 | -43.56 |
| Operating Cash Flow | -30.21 | -37.94 | -48.28 | -65.95 | -24.09 | 109 | -25.82 | -20.47 | -12.95 | -13.27 |
| Capital Expenditures | 0.08 | 0.12 | 0.21 | -2.25 | -4.00 | -1.70 | -1.39 | -1.27 | -0.28 | -2.93 |
| Free Cash Flow | -30.13 | -37.82 | -48.07 | -68.19 | -28.08 | 107 | -27.20 | -21.74 | -13.23 | -16.20 |
| Cash & Equivalents | 4.95 | 121 | 159 | 131 | 198 | 203 | 61.54 | 21.74 | 41.98 | 12.84 |
| Total Debt | 0.38 | 0.10 | 0.33 | 0.91 | 1.83 | 14.10 | 1.22 | 1.38 | 7.16 | 7.29 |
| Net Cash / Debt | 4.57 | 121 | 158 | 131 | 196 | 189 | 60.32 | 20.36 | 34.82 | 5.55 |
| Assets | 5.53 | 131 | 181 | 175 | 219 | 231 | 70.56 | 29.43 | 48.38 | 20.08 |
| Liabilities | 1.45 | 15.80 | 29.14 | 45.28 | 22.77 | 34.29 | 12.23 | 11.50 | 11.61 | 10.35 |
| Book Value | -59.46 | 115 | 152 | 129 | 196 | 197 | 58.33 | 17.93 | 36.77 | -54.96 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Lumos Pharma, Inc. |
| Country |
United States |
| Employees |
27 |
| CEO |
Richard J. Hawkins |
Stock Information
| Ticker Symbol |
LUMO |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: LUMO |
Description
Lumos Pharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for severe, rare, and genetic diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone stimulating small molecule, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency. The company has a licensing agreement with Ellipses Pharma Limited for the development of and rights to commercialize nanoparticle formulations of two therapeutics for oncology indications. Lumos Pharma, Inc. was founded in 2011 and is headquartered in Austin, Texas.